<DOC>
	<DOCNO>NCT00850044</DOCNO>
	<brief_summary>The purpose study determine pharmacokinetic safety profile experimental HCV protease inhibitor without ritonavir healthy volunteer .</brief_summary>
	<brief_title>Safety , Tolerability PK Study Single Doses ABT-450 With Without Ritonavir Treat Hepatitis C Virus ( HCV ) Genotype 1</brief_title>
	<detailed_description />
	<mesh_term>Ritonavir</mesh_term>
	<criteria>overall healthy subject nonchildbearing potential female include history significant sensitivity drug positive test HAV IgM , HBsAg , antiHCV Ab antiHIV Ab history gastrointestinal issue procedure history seizure , diabetes cancer ( except basal cell carcinoma ) clinically significant cardiovascular , respiratory ( except mild asthma ) , renal , gastrointestinal , hematologic , neurologic , thyroid , uncontrolled medical illness psychiatric disorder use tobacco nicotinecontaining product 6month period prior study drug administration donation loss 550 mL blood volume receipt transfusion blood product within 8 week prior study drug administration abnormal screen laboratory result consider clinically significant investigator current enrollment another clinical study previous enrollment study recent ( 6month ) history drug/alcohol abuse could preclude adherence protocol pregnant breastfeed female requirement OTC and/or prescription medication , vitamins and/or herbal supplement regular basis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>FIH</keyword>
	<keyword>SAD</keyword>
</DOC>